Stargardt Disease 1 Clinical Trial
Official title:
Prospective, Randomised, Double-blind Study to Assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS
Prospective, randomised, double-blind study to assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS.
Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. By the year 2040, the number of people suffering from AMD is estimated to increase by 50%. Stargardt disease is the most prevalent form of macular dystrophy in children, with an estimated prevalence of 1 in 10000. There is no effective treatment available that stops progression or improves vision in patients with dry AMD or Stargardt disease. Considering the success in animal studies and observational human studies with omega-3 fatty acids supplementation when the blood ratio AA (arachidonic acid)/EPA (eicosapentaenoic acid) is <2, the sponsor hypothesizes that, when the blood ratio of AA/EPA is maintained below 2, the visual acuity in the group with active supplements will improve, in comparison to the control group, in patients with moderate and severe dry AMD and moderate and severe Stargardt. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04281732 -
Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision
|
||
| Recruiting |
NCT05258032 -
Structural and Functional Characterization of Rare Ocular Diseases
|
||
| Active, not recruiting |
NCT06300476 -
Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05674058 -
Function and Imaging Assessments for G1961E-associated Stargardt Disease
|
||
| Active, not recruiting |
NCT05244304 -
Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1
|
Phase 3 | |
| Not yet recruiting |
NCT06388083 -
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03364153 -
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
|
Phase 2 | |
| Enrolling by invitation |
NCT03772938 -
Stem Cells Therapy in Degenerative Diseases of the Retina
|
Phase 1 |